Inside the Investor’s Mind: What fundable companies look like in 2026
What makes a biotech company fundable in 2026? Leading investors reveal the science, data, manufacturing and strategy milestones that drive funding decisions.
The Investment Summit opens with Christiaan Engstrom, Founder of BLPN, sharing perspectives on capital, strategy and the evolving future of advanced therapies investment.
Biotech funding is evolving. Explore alternative capital models, structured liquidity and new investor types shaping how emerging companies fund innovation.
Join the industry in Barcelona | 7 - 9 September 2026 for 3 days of deal-making, data-driven insight and serious momentum across cell and gene therapy. From early science to commercial scale, this is where the full ecosystem connects, collaborates and moves the field forward.